Recent Updates
Recently added Catalysts
VALN Positive Sentiment

Rapport Semestriel 2026 Valneva

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Valneva SE has reported positive developments regarding its Lyme disease vaccine candidate, which is a collaboration with Pfizer. The European Medicines Agency has validated their marketing authorization application based on promising results from the Phase 3 VALOR trial. This marks a significant step forward for Valneva in the vaccine market.
Price reaction · baseline $5.53 (2026-08-13T15:29:00.000Z) · hit during market hours · clean, no other VALN news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Valneva's Lyme disease vaccine candidate shows favorable efficacy.
  • The marketing authorization application has been validated by EMA.
  • Partnership with Pfizer enhances credibility and resources.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
3.7%
average across 6 past catalysts
Lead asset
VLA1553 full dose
Phase 2 · Chikungunya Virus Infection

Full Press Release Details

Pièce jointe
• Financial Report HY1 2026 (FR) (2026-08-12) (002)

Recommended Reading

• September 04, 2026 12:00 ET | Source: VALNEVA SE Declaration of shares and voting rights - Status as of August 31, 2026 VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name:... Read More
• August 14, 2026 01:00 ET | Source: VALNEVA SE Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris:... Read More
VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name:...
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris:...

Frequently Asked Questions

What is the status of Valneva's Lyme disease vaccine?

Valneva's Lyme disease vaccine candidate has received validation from the EMA.

What trial results support Valneva's vaccine application?

The application is based on favorable results from the Phase 3 VALOR trial.

Who is partnering with Valneva on the Lyme vaccine?

Valneva is collaborating with Pfizer on the Lyme disease vaccine candidate.

When was the EMA validation announced?

The EMA validation was announced on August 14, 2026.

ShareAdd on Google
Tags: VALN Valneva Lyme disease vaccine Pfizer EMA
Last updated: Aug 13, 2026

Biotech snapshot

Lead asset
VLA1553 full dosePhase 2
Chikungunya Virus Infection →

Catalyst track record

+8%
best trade around VALN's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VALN.

See every catalyst's timing & PoA →